Increased dyslipidemia in schizophrenic outpatients using new generation antipsychotics

Revista Brasileira de Psiquiatria

Volumn 28, Issue 4, 2006, Pages 301-304

  Leitão Azevedo, Carmen Lúcia ^a,c   Guimarães, Lísia Rejane ^a   De Abreu, Martha Guerra Belmonte ^a   Gama, Clarissa Severino ^b   Lobato, Maria Inês ^b   Belmonte de Abreu, Paulo Silva ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c NONE   (Brazil)

Author keywords

Antipsychotics agents; Dyslipidemias; Lipids; Obesity; Schizophrenia

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; GLUCOSE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN; LEVOMEPROMAZINE; LIPID; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TRIACYLGLYCEROL; ZIPRASIDONE;

ADULT; ANTHROPOMETRY; ARTICLE; BODY MASS; BRAZIL; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MONOTHERAPY; SCHIZOPHRENIA; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL; DYSLIPIDEMIAS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; OBESITY; SCHIZOPHRENIA; SEX FACTORS; TRIGLYCERIDES;

EID: 33846536679     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-44462006005000016     Document Type: Article

References (15)

1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-96.
2. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care. 2004;27(8):596-601.
3. Halpern A, Segal A, Ribeiro AB, Garrido A, Mady C, Fernandes F, Lorenzi G Fo, Ramires JA, Zanela MT, Grinberg M, Macini M. Diretrizes para Cardiologistas sobre Excesso de Peso e Doença Cardiovascular dos Departamentos de Aterosclerose, Cardiologia Clínica e FUNCOR da Sociedade Brasileira de Cardiologia. Arq Bras Cardiol. 2002;78(Suppl 1):1-13.
4. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC. Clozapine: diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 2000;157(6):975-81.
5. Meyer JM. A retrospective comparison of lipid, glucose, and weight changes at one year between olanzapine and risperidone treated inpatients. In: Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology. Nashville, Tenn: ACNP; 2000.
6. Azevedo MH, Valente J, Macedo A, Dourado A, Coelho I, Pato M, Pato C. Versão portuguesa da "Entrevista Diagnóstica para Estudos Genéticos". Psiquiatr Clin. 1993;14(4):213-7.
7. Expert panel on detection evaluation and treatment of high blood cholesterol in adults. Executive summary of the third Report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA. 2001;285(19):2486-97.
8. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160-7.
9. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Secretaria de Atenção à Saúde, Instituto Nacional do Câncer. Coordenação de Prevenção e Vigilância. Inquérito domiciliar sobre comportamentos de risco e morbidade referida de doenças e agravos não transmissíveis: Brasil, 15 capitais e Distrito Federal 2002-2003. Rio de Janeiro: INCA; 2004. 186 p. [citado 2 fev 2005] Disponíivel em: http://www.inca.gov.br/inquerito/.
10. Mackin P, Watkinson HM, Young AH. Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia. 2005;48(2):215-21.
11. Kato MM, Currier MB, Villaverde O, Gonzalez-Blanco M. The relation between body fat distribution and cardiovascular risk factors in patients with schizophrenia: a cross-sectional pilot study. Prim Care Companion J Clin Psychiatry. 2005;7(3):115-8.
12. International Psychopharmacology Algorithm Projet (IPAP). Metabolic Side Effects and Management. 2004. [cited 2 fev 2005]. Available at: http://www.ipap.org/schiz/.
13. Sernyak MJ, Gulanski B, Leslie DL, Rosenheck R. Undiagnosed hyperglycemia in clozapine-treated patients with schizophrenia. J Clin Psychiatry. 2003;64(5):605-8.
14. Subramaniam M, Chong SA, Pek E. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry. 2003;48(5):345-7.
15. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL. Diabetes mellitus in schizophrenic patients. Compr Psychiatry. 1996;37(1):68-73.